PubMed Health⌕ Search

Biomedical subjects

J J Gonvers

Publications and source records attributed to J J Gonvers.

At least 127 records · Page 7Linked to original sources
PubMed1982

[Treatment of reflux esophagitis with ranitidine. A multicentric prospective study].

Thirty-eight patients with erosive-ulcerative reflux esophagitis were treated in an open trial with the histamine-H2-receptor antagonist ranitidine (150 mg twice daily). At endoscopy after 6 weeks there was evidence of complete healing of all epithelial defects in 20 of 38 patients (53%). Continuation of treatment for another 6 weeks in 13 patients was followed by healing in 6 additional patients as judged by endoscopy. Although the symptoms of the group as a whole improved significantly during treatment, there was no correlation between the degree of symptomatic improvement and healing of esophagitis. Also, the healing rate did not depend on age, sex, smoking and drinking habits or on the severity of esophagitis. It is concluded that medical treatment of reflux esophagitis with ranitidine is promising, even in severe cases previously considered candidates for surgery.

Anti-Ulcer Agents↗
PubMed1982

[Hematemesis].

Explore the source record for details and available documents.

Adult↗
PubMed1982

[Treatment and prevention of recurrence of duodenal ulcer with pirenzepin and cimetidine].

The effect of pirenzepine and cimetidine on healing, symptoms, and relapse rate of duodenal ulcer was studied in a placebo controlled double blind trial. With regard to symptoms, cimetidine (1 g daily) was superior at the beginning of therapy to a low dose of pirenzepine (75 mg daily) and to placebo. No significant differences in ulcer healing were found between the 3 treatment groups. The relapse rate after treatment with pirenzepine was lower than after treatment with cimetidine.

Adult↗
PubMed1982

Treatment and relapse prophylaxis of duodenal ulcer with pirenzepine and cimetidine.

The effect of pirenzepine and cimetidine on healing, symptoms and relapse rate of duodenal ulcer was studied in a placebo-controlled double-blind trial. Cimetidine (1 g daily) was superior at the beginning of therapy to a low dose of pirenzepine (75 mg daily) and placebo with regard to symptoms. No significant differences in ulcer healing were found between the 3 groups of treatment. The relapse rate after treatment with pirenzepine was lower than after treatment with cimetidine.

Adult↗
PubMed1981

[Treatment of refractory ascites by means of the LeVeen shunt].

Amongst the surgical treatments that have been suggested for refractory ascites, the one that has met with the greatest success is the LeVeen shunt. It nevertheless involves certain risks and might even be fatal. The authors' brief experience in this domain has confirmed its positive immediate effects and has also brought to light some of its drawbacks. The large number of potential complications leads one to conclude that the LeVeen shunt should be reserved for refractory ascites and hepato-renal syndrome, and should not be prematurely employed in other situations.

Aldosterone↗
PubMed1981

Predictors of duodenal ulcer healing and relapse.

Predictors of duodenal ulcer healing and relapse were examined in a population known to have a high healing incidence. Two double-blind prospective studies were performed in 134 patients over 4 wk and in 66 patients over 1 yr, respectively. Short-term treatment consisted either of cimetidine 1 g/day, pirenzepine 75 mg/day, or placebo. In a multiple stepwise linear regression analysis the following factors proved to increase healing incidence in decreasing order of importance: female sex, moderate alcohol consumption, abstinence from smoking, young age, and cimetidine treatment. The following factors had no influence on duodenal ulcer healing: number and total area of peptic lesions, concomitant disease, relatives with duodenal ulcer, duration of duodenal ulcer disease, and status as a migrant worker. In the long-term study, treatment consisted either of cimetidine 400 mg at bedtime, pirenzepine 30 mg at bedtime, or placebo. Cimetidine prevented ulcer relapse. Smoking favored duodenal ulcer relapse in the placebo group, but not in the cimetidine and pirenzepine group. For all the other factors no statistically significant effect was found. It is concluded that in a population with high spontaneous healing incidence (a) factors other than drug treatment such as sex, alcohol intake, smoking, and age are at least as important predictors of the outcome of short-term treatment as the drug treatment itself; (b) moderate alcohol intake might favor ulcer healing; (c) the unfavorable effect of smoking on ulcer relapse is overcome by low-dose, long-term, antisecretory treatment.

Adult↗
PubMed1980

[Cirrhotic ascites and the renin-angiotensin system].

Plasma renin activity and plasma aldosterone have been measured in 31 patients in different clinical stages of alcoholic cirrhosis. Plasma renin activity and plasma aldosterone were within the normal range in patients with compensated cirrhosis and in patients with untreated cirrhosis and ascites. These results are not in keeping with the traditional concepts of reduced "effective' blood volume with stimulation of the renin-angiotensin system. In ascites treated with diuretics, and in the hepato-renal syndrome, the renin-angiotensin system was, however, stimulated. Peritoneo-venous shunt was followed by suppression of this stimulation.

Aldosterone↗
PubMed1980

[Plasma glucagon in alcoholic cirrhosis: cross reaction with IgG].

Glucagon secretion has been tested in 12 cirrhotic patients and the results have been compared with those obtained in 10 normal subjects. Two antisera reputed to be specific for glucagon (antiserum 30-K and antiserum RCS5) were used. The patients with cirrhosis exhibited significantly higher levels of plasma immunoreactivity for glucagon, suggesting hyperglucagonemia when using antiserum 30-K but not when using antiserum RCS 5. A positive correlation (r = 0.527, p less than 0.001) was found between plasma immunoreactive glucagon measured by antiserum 30-K and IgG. With antiserum RCS 5 there was no such correlation. These data suggest that hyperglucagonemia may be wrongly suspected when glucagon is measured with antiserum 30-K, due to cross-reaction with IgG. Cirrhotic patients exhibit only a slight increase of glucagon.

Cross Reactions↗
PubMed1980

The histological patterns of chronic active hepatitis--excluding cirrhosis--and their prognostic significance.

In a retrospective clinico-pathological analysis of 30 cases of chronic active hepatitis, no significant correlation could be demonstrated between any histological feature and the end result of the evolution. The so-called "bridging" lesion, in particular, has no prognostic value. A possible effect of the therapy (cortico-steroids or not) on the final outcome could not be established. There is however a clearcut difference in the rate of development, be it favorable or not, between the slow progress of chronic aggressive hepatitis, and the rapidly changing subacute hepatitis. We therefore feel that such a distinction should be maintained, and question the nomenclature proposed by the International Association for Study of the Liver.

Chronic Disease↗
PubMed1980

[Initial experiences with peritoneo-venous shunting by means of the Le Veen pressure-sensitive valve in the treatment of refractory ascites].

Of all different surgical treatments of ascites, the peritoneo-venous shunt actually seems to be the less risky method. Our short experience confirms the success of this method, but also its contradictions and reveals a little known complication: the thrombosis of the superior vena cava. Its superiority over the lympho-venous anastomosis has been proven in one of our patients.

Adult↗
PubMed1979

[Treatment of cirrhotic ascites].

The treatment of cirrhotic ascites is based on restriction of dietary sodium and fluid intake coupled with diuretics. Ascitic fluid must always be sampled and infection ruled out. Large abdominal paracenteses are dangerous. Most patients with ascites respond to the dietary-diuretic regimen. The clinician must be watchful for overdiuresis. Some patients need diuretics in ever-increasing doses in an attempt to increase urine flow and are at particular risk of functional renal failure. In these diuretic-resistant cases the ascitic fluid can be withdrawn, ultra-filtered and reinfused by means of suitable apparatus. In 1974, LeVeen and co-workers described a peritoneo-venous shunt system which provides more continuous treatment over many months. The morbidity and mortality of this shunt are difficult to determine from published reports. Long-term controlled studies are needed. The beneficial effect on survival of treatment of cirrhotic ascites is still questioned.

Ascites↗
PubMed1979

[Therapy of duodenal ulcer with cimetidine, pirenzipine and placebo: report on a double-blind randomized study].

A double-blind randomized controlled study with pirenzepine (75 mg/day), cimetidine (1 g/day) and placebo was performed in 50 consecutive out-patients with duodenal ulcer. The patients also received an antacid containing aluminium hydroxide. Pirenzepine, cimetidine and placebo had similar effects on the 4-week healing rate. Dryness of the mouth was more frequent with pirenzepine than with the other two types of treatment. The incidence of other side effects did not differ in the three groups. A tendency towards more rapid disappearance of subjective symptoms in the patients treated with pirenzepine was not statistically significant. In conclusion, pirenzepine and cimetidine were not superior to placebo in the treatment of duodenal ulcer.

Adult↗